Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model

Figure 3 Effect of rAAV-endostatin in combination with etoposide on murine sarcoma bearing mice. Twenty five mice bearing S-180 murine sarcoma cells were randomly divided into 5 groups, namely no treatment, rAAV-LacZ alone, rAAV-LaZ plus etoposide pretreatment, rAAV-endostatin alone, and rAAV-endostatin plus etoposide pretreatment. In the pretreat-ment group, etoposide (40 mg/kg) was administered 3 times for one week by an intraperitoneal injection beginning 7 d prior to rAAV injection, and 1.5 × 10¹² viral particles of rAAV- rAAVendostatin vector were injected into the spleen simultaneously with tumor cell inoculation (5 × 106 S-180 cells) into the liver. The tumor volume was determined 7 d after injecting murine sarcoma cells (P < 0.05, rAAV plus etoposide group versus other groups). Tumor volume = (Length×width2)/2.